Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism

Seminars in Surgical Oncology

Volumn 13, Issue 2, 1997, Pages 78-86

  Tominaga, Yoshihiro ^a   Tanaka, Yuji ^b   Sato, Kesisuke ^b   Nagasaka, Takaharu ^b   Takagi, Hiroshi ^b  

^a NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

calcitriol receptors; chronic renal failure; hyperplasia; parathyroid glands; parathyroid hormone; parathyroidectomy; secondary hyperparathyroidism

Indexed keywords

ARTICLE; CALCIUM METABOLISM; CHRONIC KIDNEY DISEASE; HISTOPATHOLOGY; HUMAN; PARATHYROID HORMONE RELEASE; PARATHYROID HYPERPLASIA; PARATHYROIDECTOMY; PRIORITY JOURNAL; RECEPTOR DENSITY; SECONDARY HYPERPARATHYROIDISM; VITAMIN INTAKE;

CELL DIVISION; DNA; HUMANS; HYPERPARATHYROIDISM, SECONDARY; HYPERPLASIA; KIDNEY FAILURE; PARATHYROID GLANDS; PARATHYROID HORMONE; RECEPTORS, CALCITRIOL;

EID: 0030992925     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(199703/04)13:2<78::AID-SSU3>3.0.CO;2-Z     Document Type: Article

References (68)

1. Albright F, Baird PC, Cope O, Bloomberg E: Studies on the physiology of parathyroid glands. IV. Renal complications of hyperparathyroidism. Am J Med Sci 1934,187:49-65.
2. Llach F: Secondary hyperparathyroidism in renal failure: The trade-off hypothesis revisited [review]. Am J Kidney Dis 1995;25:663-679.
3. Åkerström G, Malmaeus J, Grimelius L, et al: Histological changes in parathyroid glands in subclinical and clinical renal disease. An autopsy investigation. Scand J Urol Nephrol 1984;18:75-84.
4. Akizawa T, Fukagawa M, Koshikawa S, Kurokawa K: Recent progress m management of secondary hyperparathyroidism of chrome renal failure. [Review] Curr Opin Nephrol Hypertens 1993;2:558-565
5. Parfitt AM: Parathyroid growth. In Bilezikian JP, Marcus R, Levine MA (eds): "The Parathyroids." New York: Raven Press, 1993:373-405.
6. Brown EM, Gamba G, Riccardi D, et al: Cloning and characterization of an extracellular Ca (2+)-sensing receptor from bovine parathyroid. Nature 1993;366(6455):575-580.
7. Garrett JE, Capuano IV, Hammerland LG, et al: Molecular cloning and functional expression of human parathyroid calcium receptor cDNAs. J Biol Chem 1995;270:18919-12925.
8. Brown EM, Pollak M, Hebert SC: Sensing extracellular Ca2+ by parathyroid and kidney cells: cloning and characterization of an extracellular Ca (2+)-sensing receptor. [Review] Am J Kidney Dis 1995;25:506-513.
9. Rothmund M: Surgical treatment of secondary hyperparathyroidism: indication, operative management and result. Prog Surg 1986;18:186-205.
10. Llach F: Parathyroidectomy in chronic renal failure: Indications, surgical approach and use of calcitriol. Kidney Int Suppl 1990;29:S62-S68.
11. Ritz E, Matthias S, Seidel A, et al: Disturbed calcium metabolism in renal failure-pathogenesis and therapeutic strategies. [Review] Kidney Int Suppl 1992;38:537-542.
12. Tominaga Y, Numano M, Uchida K, et al: Parathyroidectomy for patients with renal hyperparathyroidism refractory to calcitriol pulse therapy. J Bone Miner Metab 1994;12:S99-S104.
13. Malmaeus J, Grimelius L, Johansson H, et al: Parathyroid pathology in hyperparathyroidism secondary to chronic renal failure. Scand J Urol Nephrol 1984;18:157-166
14. Grimelius L, Åkerström G, Johansson H, et al: Parathyroid gland. In Kovacs K, Asa SL (eds): "Functional Endocrine Pathology." Cambridge, MA: Blackwell, 199:375.
15. Takagi H, Tominaga Y, Uchida K, et al: Polymorphism of parathyroid glands in patients with chronic renal failure and secondary hyperparathyroidism. Endocrinol Jpn 1983;30:463-468.
16. Tominaga Y, Sato K, Tanaka Y, et al: Histopathology and pathophysiolosy of secondary hyperparathyroidism due to chronic renal failure. Clin Nephrol 1995;44 Suppl:S42-S47.
17. Tominaga Y, Grimelius L, Johansson H, et al: Histological and clinical features of nonfamilial primary parathyroid hyperplasia. Pathol Res Pract 1992;188:115-122.
18. Oka T, Yoshioka T, Shrestha GR, et al: Immunohistochemical study of nodular hyperplastic parathyroid glands in patients with secondary hyperparathyroidism. Virchows Arch A Pathol Anal Histopathol 1988;413:53-60.
19. Tominaga Y, Tanaka Y, Sato K, et al: Recurrent renal hyperparathyroidism and DNA analysis of autografted parathyroid tissue. World J Surg 1992;16:595-603.
20. Tominaga Y, Grimelius L, Falkmer UG, et al: DNA ploidy pattern of parathyroid parenchymal cells in renal secondary hyperparathyroidism. Anal Cell Pathol 1991;3:325-333.
21. Tominaga Y, Tanaka Y, Sato K, et al: DNA studies in graft-dependent hyperparathyroidism. Acta Chir Austrica 1996;124:65-68.
22. Ohta K, Manabe T, Katagiri M, Harada T: Expression of proliferating cell nuclear antigens in parathyroid glands of renal hyperparathyroidism. World J Surg 1994;18:625-629.
23. Loda M, Lipman J, Cukor B, et al: Nodular foci in parathyroid adenomas and hyperplasias: an immunohistochemical analysis of proliferative activity. Hum Pathol 1994;25:1050-1056.
24. Vogelstein B, Fearon ER, Hamilton SR, Feinberg AP: Use of restriction fragment length polymorphism to determine the clonal origin of human tumors. Science 1985;227(4687):642-645.
25. Gilliland DG, Blanchard KL, Levy J, et al: Clonality in myeloproliferative disorders: Analysis by means of the polymerase chain reaction. Proc Natl Acad Sci USA 1991;88:6848-6852.
26. Noguchi S, Motomura K, Inaji H, et al: Clonal analysis of parathyroid adenoma by means of the polymerase chain reaction. Cancer Lett 1994;78:93-97.
27. Tominaga Y, Kohara S, Namii Y, et al: Clonal analysis of nodular parathyroid hyperplasia in renal hyperparathyroidism World J Surg 1996;20:744-752.
28. Arnold A, Brown MF, Urena P, et al: Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest 1995;95:2047-2053.
29. Tominaga Y, Takagi H: Molecular genetics of hyperparathyroid disease. Curr Opin Nephrol Hypertens 1996;5:336-341.
30. Falchetti A, Bale AE, Amorosi A, et al: Progression of uremic hyperparathyroidism involves allelic loss on chromosome 11. J Clin Endocrinol Metab 1993;76:139-144.
31. Arnold A, Kim HG, Gaz RD, et al: Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma. J Clin Invest 1989;83:2034-2040.
32. Rosenberg CL, Kim HG, Shows TB, et al: Rearrangement and overexpression of D11 S287E, a candidate oncogene in chromosome 11q13 in benign parathyroid tumors. Oncogene 1991;6:449-453.
33. Motokura T, Bloom T, Kim HG, et al: A novel cyclin encoded by a bcl I-linked candidate oncogene. Nature 1991;350(6318):512-515.
34. Muller H, Lukas J, Schneider A, et al: Cyclin D1 expression is regulated by the retinoblastoma protein. Proc Natl Acad Sci USA 1994;91:2945-2949.
35. Hsi ED, Zukerberg LR, Yang WI, Arnold A: Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study. J Clin Endol Metab 1996;81:1736-1739.
36. Tominaga Y, Numano M, Uchida K, et al: Lung metastasis from parathyroid carcinoma causing recurrent renal hyperparathyroidism in hemodialysis patients: report of a case. Surg Today 1995,25:984-986.
37. Cryns VL, Thor A, Xu HJ, et al: Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma. N Engl J Med 1994;330:757-761.
38. Yamamoto M, Igarashi T, Muramatsu M, et al: Hypocalcemia increases and hypercalcemia decreases the steady-state level of parathyroid hormone messenger RNA in the rat. J Clin Invest 1989;83:1053-1056.
39. Okazaki T, Igarashi T, Kronenberg KM: 5′-flanking region of the parathyroid hormone gene mediates negative regulation by 1,25-(OH)2 vitamin D3. J Biol Chem 1988;263:2203-2208.
40. Nygren P, Larsson R, Johansson H, et al: 1,25(OH)2D3 inhibits hormone secretion and proliferation but not functional dedifferentiation of cultured bovine parathyroid cells. Calcif Tissue Int 1988;43:213-218.
41. Shvil Y, Naveh-Many T, Barach P, Silver P: Regulation of parathyroid cell gene expression in experimental uremia. J Am Soc Nephrol 1990;1L99-104.
42. Szabo A, Merke J, Beier E, et al: 1,25(OH)2 vitamin D3 inhibits parathyroid cell proliferation in experimental uremia. Kidney Int 1989;35:1049-1056.
43. Naveh-Many T, Rahamimov R, Livni N, Silver J: Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D. J Clin Invest 1995;95:1786-1793.
44. Yi H, Fukagawa M, Yamato H, et al. Prevention of enhanced parathyroid hormone secretion, synthesis and hyperplasia by mild dietary phosphorus restriction in early chronic renal failure in rats: possible direct role of phosphorus. Nephron 1995;70:242-248.
45. Slatopolsky E, Finch J, Denda M, et al: Phosphorus restriction parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 1996;97:2534-2540.
46. Massry SG: Role of 1,25(OH)2D3 in the genesis of secondary hyperparathyroidism of early renal failure and its use in the prevention of this abnormality. Metabolism 1990;39 (4 Suppl 1):13-17.
47. Slatopolsky E, Weerts C, Thielan J, et al: Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 1984;74:2136-2143.
48. Naveh-Many T, Marx R, Keshet E, et al: Regulation of 1,25-dihydroxyvitamin D3 receptor gene expression by 1,25-dihydroxyvitamin D3 in the parathyroid in vitro. J Clin Invest 1990;86:1968-1975.
49. Reichel H, Szato A, Uhl J: Intermittent venous continuous administration of calcitriol: Comparison of efficacy (Abstract). Nephrol Dial Transplant 1992;7:762.
50. Delmez JA, Tindira C, Grooms P, et al: Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D. A role for increased sensitivity to calcium. J Clin Invest 1989;83.1349-1355.
51. Tanaka Y, Seo H, Tominaga Y, et al: factors related to recurrent hyperfunction of autografts after total parathyroidectomy in patients with severe secondary hyperparathyroidism. Surg Today 1993;23:220-227.
52. Fukagawa M, Kaname S, Igarashi T, et al: Regulation of parathyroid hormone synthesis in chronic renal failure in rats. Kidney Int 1991;39:874-881.
53. Brown EM, Wilson RE, Eastman RC, et al: Abnormal regulation of parathyroid hormone release by calcium in secondary hyperparathyroidism. J Clin Endocrinol Metab 1982;54:172-177.
54. Wallfelt CH, Larsson R, Gylfe E, et al: Secretary disturbance in hyperplastic parathyroid nodules in uremic hyperparathyroidism: Implication for parathyroid autotransplantation. World J Surg 1988;12:431-438.
55. Johansson H, Rastad J, Bjerneroth G, et al: Microfluorometric measurements of cytoplasmic calcium in chief and oxyphil parathyroid cells of adenomatous and hyperplastic glands and of normal-sized glands associated with adenomas. Surgery 1989;106:517-524.
56. Kifor O, Moore FD Jr, Wang P, et al: Reduced immunostaining for the extracellular Ca2+sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 1996,81:1598-1606.
57. Gogusev J, Duchambon P, Hory B, et al: Parathyroid tissue expression of the Ca-sensing receptor in primary and secondary hyperparathyroidism [abstract]. In European Renal Association/European Dialysis and Transplant Association 33rd congress program; 1996 June 18-21; Amsterdam. 1996:267.
58. Chou YH, Brown EM, Levin T: The gene responsible for familial hypocalciuric hypercalcemia maps to chromosome 3q in four unrelated families. Nature Genetics 1992;1:3-6.
59. Pollak MR, Brown EM, Chou YH, et al: Mutations in the human Ca(2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 1993;75:1297-1303
60. Hosokawa Y, Pollak MR, Brown EM, Arnold A: Mutational analysis of the extracellular Ca(2+)-sensing receptor gene in human parathyroid rumors. J Clin Endocrinol Metab 1995,80.3107-3110.
61. Juhlin C, Klareskog L, Nygren P, et al: Hyperparathyroidism is associated with reduced expression of parathyroid calcium receptor mechanism defined by monoclonal antiparathyroid antibodies. Endocrinology 1988;122 2999-3001.
62. Lundgren S, Hjalm G, Hellman P, et al: A protein involved in calcium sensing of the human parathyroid and placental cytotrophoblast cells belongs to the LDL-receptor protein superfamily. Exp Cell Res 1994;212:344-350.
63. Korkor AB: Reduced binding of [3H] 1,25-dihydroxy vitamin D3 in the parathyroid glands of patients with renal failure. N Engl J Med 1987;316:1573-1577.
64. Fukuda N, Tanaka H, Tominaga Y, et al: Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993;92:1436-1443.
65. Fournier A, Moriniere P, Oprisiu R, et al: 1-alpha-hydroxyvitamin D3 derivatives in the treatment of renal bone disease: justification and optimal modalities of administration. [Review] Nephron 1995;71:254-283.
66. Fukagawa M, Kitaoka M, Yi H, et al: Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients. Nephron 1994;68:221-228.
67. Giangrande A, Castiglioni A, Solbiati L, Allaria P: Ultrasound-guided percutaneous fine-needle ethanol injection into parathyroid glands in secondary hyperparathyroidism. Nephrol Dial Transplant 1992;7:412-421.
68. Tominaga Y, Sato K, Numano M, et al: Surgical treatment of renal hyperparathyroidism. Asian J Surg 1994;17:121-126.